Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingAetna lung imaging coverage & policy update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0581

    Lung Imaging: Selected Techniques

    Customize your policy alerts

    Sign up for Aetna Policy 0581 alerts

    Get alerted when Policy 0581 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governance of medical necessity and experimental/investigational status for selected lung imaging techniques (including LIFE/autofluorescence bronchoscopy, Raman spectroscopy, pulmonary tissue ventilation analysis, and hyperpolarized Xe-129 MRI) for Aetna members and providers.

    Policy Summary
    PayerAetna
    PolicyLung Imaging: Selected Techniques
    Policy CodePolicy 0581
    Change TypeNo material changes
    Effective DateNov 16, 2001
    Last ReviewNov 10, 2023
    Next Review DateJun 27, 2024
    Key ActionWhen using LIFE/autofluorescence bronchoscopy, document that it was performed in conjunction with white-light bronchoscopy and record the clinical indication consistent with the policy's specified high-risk or suspected lung cancer groups.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50%detection increase
    1.50xOnco-LIFE sensitivity
    0807T, C9150non-covered examples
    FDA (Dec 2022)Xe-129 approval
    11/16/2001policy effective
    11/10/2023last review

    Coverage Criteria

    Medical necessity for LIFE / autofluorescence bronchoscopy

    Aetna considers LIFE (autofluorescence bronchoscopy) medically necessary to enhance detection and biopsy of abnormal bronchial tissue when used in conjunction with white-light bronchoscopy in any of the following groups:

    Indicated groups: 1) Members with known or previously diagnosed lung cancer; OR 2) Members with suspected lung cancer including: a) Members suspected because of clinical symptoms such as positive sputum cytology, hemoptysis, unresolved pneumonia, persistent cough or positive chest x-ray; OR b) Members with a previously resected Stage I lung cancer, with no evidence of metastatic disease, who are at risk for secondary disease.

    LIFE use must be in conjunction with white-light bronchoscopy and operator must be trained in flexible fiber optic bronchoscopy and LIFE device use.

    Experimental and Investigational

    Aetna considers the following modalities experimental and investigational because effectiveness has not been established:

    Experimental/Investigational modalities: 1) LIFE for all indications not listed in the medical necessity section; 2) Point laser Raman spectroscopy combined with white-light bronchoscopy and autofluorescence bronchoscopy for detection of pre-neoplastic lesions; 3) XV LVAS pulmonary tissue ventilation analysis for quantification of pulmonary tissue ventilation; 4) Xenon Xe-129 hyper-polarized gas (Xenoview) for evaluation of lung ventilation.
    Policy Summary
    PayerAetna
    PolicyLung Imaging: Selected Techniques
    Policy CodePolicy 0581
    Change TypeNo material changes
    Effective DateNov 16, 2001
    Last ReviewNov 10, 2023
    Next Review DateJun 27, 2024
    Key ActionWhen using LIFE/autofluorescence bronchoscopy, document that it was performed in conjunction with white-light bronchoscopy and record the clinical indication consistent with the policy's specified high-risk or suspected lung cancer groups.
    SourceLink
    On This Page
    Coverage CriteriaCovered and Investigational IndicationsCodingProvider Actions and Operational NotesPrior Authorization ConsiderationsContrast and Agent RulesNot CoveredBackgroundDefinitionsReferences and Revision History

    These modalities are considered experimental/investigational by Aetna.

    Autofluorescence (LIFE/Onco-LIFE) examination should not be performed in persons for whom white-light bronchoscopy is contraindicated. Examples include persons with a known bleeding disorder or who are on anticoagulant therapy; persons with uncontrolled hypertension defined as systolic blood pressure > 200 mm Hg or diastolic pressure > 120 mm Hg; persons with unstable angina; those with a white blood cell count < 2,000 cells/µL or > 20,000 cells/µL; or a platelet count < 50,000/mm3.

    Fluorescence examination is also contraindicated for persons who have recently received agents or treatments that could affect fluorescence signal or safety: chemo-preventive drugs (for example, retinoic acid) within 3 months, systemic cytotoxic chemotherapy within 6 months, fluorescent photosensitizing agents (hematoporphyrin derivatives) within 3 months, or ionizing radiation to the chest within 6 months.

    The policy notes that several emerging lung imaging technologies remain investigational pending definitive clinical research. Xenon Xe-129 hyperpolarized-gas MRI has shown promising physiologic measures associated with disease progression in preliminary studies but is described as still awaiting definitive clinical research to establish clinical benefit; multiple active clinical trials are ongoing.

    Software-assisted pulmonary tissue ventilation analysis (XV LVAS) and image-analysis workflows (including 4D dynamic-ventilation CT with color-map software) have demonstrated promising diagnostic performance in small pilot studies for pleural invasion and localized pleural adhesion, but evidence is limited by small sample sizes and requires validation in larger studies before routine clinical use can be recommended.

    This Clinical Policy Bulletin is provided to assist in the administration of plan benefits and does not constitute an offer of coverage or medical advice. It contains only a partial, general description of plan or program benefits and is not a contract. Coverage determinations are governed by applicable plan or program provisions, and treating providers remain solely responsible for medical advice and member treatment. The bulletin may be updated and is subject to change.

    Point laser Raman spectroscopy (LRS) and other adjunctive optical techniques have shown encouraging preliminary performance when added to white-light bronchoscopy plus autofluorescence bronchoscopy in small studies (for example, high sensitivity and specificity for detection of pre-neoplastic lesions in pilot work). However, these findings are preliminary and require validation in well-designed prospective trials before routine clinical adoption. Consequently, use of point LRS and similar adjuncts is characterized as investigational in this bulletin.

    The evidence is insufficient to establish the clinical value of XV LVAS pulmonary tissue ventilation analysis and of software-assisted dynamic-ventilation CT (color-map/movie approaches) for routine care. Although small studies reported high sensitivity and specificity for specific applications (pleural invasion or localized pleural adhesion), these studies are limited by small cohorts, methodological constraints, and the need for further validation. Therefore, clinical value for these techniques is not established.

    Covered and Investigational Indications

    Autofluorescence bronchoscopy (LIFE/Onco-LIFE) as adjunct to white-light bronchoscopy

    Autofluorescence bronchoscopy indications: Autofluorescence bronchoscopy (LIFE/Onco-LIFE) as an adjunct to standard white-light bronchoscopy to enhance detection and localization of pre-invasive lesions (eg, carcinoma in situ, moderate-to-severe dysplasia) and early invasive bronchogenic carcinoma in patients who meet the medical necessity groups described in the policy.

    Clinical studies (Onco-LIFE) demonstrated increased per-lesion and per-patient sensitivity versus white-light bronchoscopy; LIFE must be used only in conjunction with white-light bronchoscopy and per device training restrictions.

    Hyperpolarized Xe-129 MRI for lung ventilation imaging

    Policy stance on hyperpolarized Xe-129 MRI: Hyperpolarized Xe-129 MRI (eg, Xenoview) provides regional lung ventilation and gas-exchange physiologic data and was FDA-approved (Dec 2022) for evaluation of lung ventilation, but Aetna lists Xenon Xe-129 hyper-polarized gas imaging as experimental and investigational for evaluation of lung ventilation in this policy version because clinical effectiveness for covered indications has not been established in routine practice.

    Technique requires specialized equipment, rapid imaging after hyper-polarization, and is discussed as investigational despite FDA approval.

    Research/diagnostic evaluation using hyper-polarized Xe-129 MRI and dynamic-ventilation CT

    Research and diagnostic evaluation contexts described in the literature (preliminary/small cohorts):

    Research / diagnostic evaluation examples: Use of hyper-polarized Xe-129 MRI (including 3D-SBCSI and spectroscopy) and research use of dynamic-ventilation CT with software-assisted analysis to: characterize regional ventilation and gas-exchange abnormalities in ILDs (eg, NSIP, IPF), COPD, CF, and post-acute COVID-19 syndrome; differentiate disease phenotypes; identify potential early markers of IPF progression; and evaluate pleural adhesion/invasion with dynamic-ventilation CT in pilot studies.

    All cited applications are preliminary and derived from small/cohort studies; clinical utility remains investigational.

    References for clinical and investigational lung imaging modalities

    Selected references supporting the statements on covered and investigational imaging modalities include:

    Literature references: References list studies addressing autofluorescence bronchoscopy (eg, Lam S, Palcic, Onco-LIFE trials), hyperpolarized 129Xe MRI (Hahn AD; Mata; Mummy; Guan; Matheson), dynamic-ventilation CT and software-assisted pleural adhesion assessment (Nagatani; Yamashiro), and device prescribing information (Polarean Xenoview).

    See the references section for numbered citations.

    Coding

    CPT codes not covered for indications in the CPBCPTNot Covered
    0807TPulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report.
    0808TIn combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report.
    Other CPT codes related to the CPBCPT
    31622Bronchoscopy, rigid or flexible, with or without fluoroscopic guidance; diagnostic, with or without cell washing (separate procedure).
    31623with brushing or protected brushings.
    31624with bronchial alveolar lavage.
    31625with bronchial or endobronchial biopsy(s), single or multiple sites.
    31628with transbronchial lung biopsy(s), single lobe.
    31629with transbronchial needle aspiration biopsy(s), trachea, main stem and/or lobar bronchus(i).
    31630with tracheal/bronchial dilation or closed reduction of fracture.
    31631with placement of tracheal stent(s) (includes tracheal/bronchial dilation as required).
    31632with transbronchial lung biopsy(s), each additional lobe (List separately in addition to code for primary procedure).
    31633with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure).
    1–10 of 15
    1/2
    HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered
    C9150Xenon xe-129 hyperpolarized gas, diagnostic, per study dose.
    C9791Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    C34.00 - C34.92Malignant neoplasm of bronchus and lung.
    C78.00 - C78.02Secondary malignant neoplasm of lung.
    D02.20 - D02.22Carcinoma in situ of bronchus and lung.
    D14.30 - D14.32Benign neoplasm of bronchus and lung.
    D38.1Neoplasm of uncertain behavior of trachea, bronchus, and lung.
    J10.00 - J18.9Pneumonia (influenza and pneumonia codes; ranges as listed).
    R04.2, R04.9Hemoptysis, unspecified.
    R04.81Acute idiopathic pulmonary hemorrhage in infants [AIPHI].
    R04.89Hemorrhage from other sites in respiratory passages.
    R05.1 - R05.9Cough.
    1–10 of 14
    1/2
    No explicit CPT/HCPCS/ICD codes in this segmentmixed
    No codes listed
    inv-13: Quantified fluorescence reflectance response — threshold and test performance
    Quantified fluorescence-reflectance thresholdOnco-LIFE quantified fluorescence reflectance response >= 0.40
    Sensitivity at threshold51% sensitivity for detection of moderate/severe dysplasia, CIS, and micro-invasive cancer
    Specificity at threshold80% specificity for detection of moderate/severe dysplasia, CIS, and micro-invasive cancer
    Per-lesion relative sensitivity (WLB+FLB vs WLB)Relative sensitivity 1.50 (95% CI: 1.26 to 1.89)
    Per-patient relative sensitivity (WLB+FLB vs WLB)Relative sensitivity 1.33 (95% CI: 1.13 to 1.70)
    inv-14: IPF progression definition used in study — FVC% and DLCO% thresholds and hospice admission
    Study definition of IPF progressionReduction in FVC% predicted by >= 10% OR reduction in DLCO% predicted by >= 15% OR admission to hospice
    Imaging/measurement endpoints usedBaseline HP 129Xe MRI and chest CT with spatial co-registration to compare RBC-to-barrier ratio and high-ventilation percentage
    Association with progressionLower baseline high-ventilation percent and lower RBC-to-barrier ratio were associated with IPF progression (p = 0.03)
    Study population22 patients with IPF (9 progressors, 13 non-progressors) and 16 healthy volunteers

    Provider Actions and Operational Notes

    Prior Authorization

    Prior Authorization Not Specified

    Prior authorization: Prior authorization is not specified in this CPB. There is no explicit requirement for prior authorization for LIFE or the other modalities discussed; however, refer to the member's specific plan/program provisions for any plan-level PA requirements.

    • Operational note: Although the CPB does not list an explicit PA requirement, provider should verify eligibility and any plan-specific prior authorization rules before scheduling.
    • Clinical Policy Bulletins assist in administering benefits but do not replace plan documents; PA rules may vary by contract.
    Prior Authorization

    Prior Authorization Guidance

    Prior authorization guidance: When prior authorization is required by the member's plan, follow the plan/program provisions and any applicable Clinical Policy Bulletin details. Providers should consult the member's benefit documents or contact Aetna/provider services to confirm PA requirements.

    • If PA is required by the specific plan, submit documentation supporting medical necessity per the CPB criteria (eg, indications listed under Medical Necessity).
    • Clinical Policy Bulletins may be updated; always use the latest CPB and plan documents when preparing PA requests.
    Note

    Radiation / Exposure Considerations

    Radiation/exposure considerations may limit routine use: Some imaging techniques (eg, 4D dynamic-ventilation CT/XV LVAS) may require additional radiation exposure. Providers should weigh potential diagnostic benefits versus increased radiation and consider alternatives or dose-reduction strategies.

    • Studies noted extra radiation exposure for dynamic-ventilation CT; lower tube current and iterative reconstruction techniques may reduce dose.
    • Radiation concerns may prompt review of clinical appropriateness before ordering these studies.
    Documentation Required

    Documentation to Support LIFE Use

    Documentation to support LIFE use: When performing LIFE (autofluorescence bronchoscopy), document that it is used in conjunction with standard white-light bronchoscopy and that the indication meets the CPB medical necessity criteria (eg, known or suspected lung cancer, prior Stage I resected lung cancer at risk for secondary disease). Also document device/training restrictions as applicable.

    • LIFE must be used with white-light bronchoscopy (eg, Olympus BF-20D) and should not be combined with photosensitizing agents.
    • Document clinical symptoms, prior diagnoses, imaging, and rationale for targeting biopsy sites identified by autofluorescence.
    • Include operator training/credentialing when relevant (LIFE is restricted by federal law to trained physicians).
    Note

    Provider Responsibility and CPB Disclaimer

    Providers are responsible for medical advice and treatment decisions; CPBs are administrative tools: Treating providers retain responsibility for medical care and should use this CPB to assist in benefits administration. The CPB is a partial description and does not constitute a contract; coverage is governed by the member's plan documents.

    • Providers must exercise clinical judgment and document rationale for chosen diagnostic approach.
    • Use the CPB to align requests with coverage criteria but confirm contract-specific terms and benefits before proceeding.
    Step Therapy

    No Step Therapy Specified

    Step therapy / other utilization management: No step therapy requirements are described in this CPB. Providers should still verify any plan-specific utilization management rules that may apply.

    • Absence of a step-therapy requirement in this CPB does not preclude plan-level limits or pathways; check member benefit details prior to service.

    Prior Authorization Considerations

    Prior Authorization

    HCPCS C9150 and C9791 (Xe‑129) listed as not covered; may require PA or be denied

    HCPCS codes C9150 and C9791 (hyperpolarized Xenon‑129 related) are listed as not covered for indications in this bulletin and may require prior authorization or be denied if submitted for non‑covered indications.

    • HCPCS: C9150 — Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
    • HCPCS: C9791 — MRI with inhaled hyperpolarized xenon-129 contrast agent, chest
    Denial Risk

    Dynamic-ventilation CT — radiation exposure may prompt pre-use review

    Several studies of dynamic-ventilation CT noted relatively high or additional radiation exposure and the bulletin highlights that these concerns may prompt review prior to routine clinical implementation.

    Contrast and Agent Rules

    Billing Rule

    Do not use LIFE with photosensitizing agents

    LIFE should not be used in combination with photosensitizing agents; this contraindication is noted in the policy background.

    • Do not combine LIFE/autofluorescence bronchoscopy with photosensitizing agents
    Billing Rule

    Xe‑129 MRI uses inhaled hyperpolarized gas — not IV contrast

    Hyper‑polarized Xe‑129 MRI uses inhaled hyperpolarized xenon‑129 gas during breath‑hold acquisitions and is not a conventional intravenous contrast agent; coding and administration reflect inhaled agent preparation and delivery rather than IV contrast.

    • Xe‑129 is inhaled for breath‑hold MRI acquisitions
    • Not a conventional IV contrast agent; includes preparation and administration of inhaled agent

    Not Covered

    When indications are not consistent with the medical necessity section of this bulletin, LIFE/autofluorescence bronchoscopy and related adjunct techniques are considered not covered. The policy specifically characterizes technologies such as XV LVAS and other investigational modalities as lacking sufficient evidence for covered use when outside the listed medically necessary indications.

    The bulletin describes several modalities as investigational or awaiting definitive research and therefore not recommended for routine clinical use for indications outside the medical necessity criteria. Providers billing for these investigational techniques may expect denials when plan provisions are not met.

    Small, preliminary case series of software-assisted dynamic-ventilation CT and XV LVAS report promising diagnostic metrics but are explicitly characterized as preliminary. These modalities remain investigational and are not established as standard of care for lung imaging indications in this bulletin.

    Adjunct optical techniques such as point laser Raman spectroscopy combined with bronchoscopy have produced high sensitivity and specificity in pilot studies, but the policy treats these as investigational pending confirmatory trials and does not list them as covered indications.

    In the absence of explicit 'not covered' listings for every modality in the excerpt, the document characterizes multiple techniques as investigational when effectiveness has not been established. Providers should treat such techniques as investigational/not covered for indications not meeting the medical necessity criteria and should consult plan provisions for final coverage decisions.

    Background

    Autofluorescence bronchoscopy systems (marketed as LIFE/Onco-LIFE) use blue excitation light transmitted via a flexible fiberoptic bronchoscope to elicit tissue autofluorescence and to enhance contrast between normal bronchial mucosa and dysplastic or carcinomatous tissue. Clinical studies (Onco-LIFE) have demonstrated that adding autofluorescence to white-light bronchoscopy increases detection rates of intra-epithelial neoplasia and early invasive carcinoma versus white-light alone, and quantitative fluorescence-reflectance metrics (for example, a threshold of >= 0.40) have been associated with improved sensitivity and specificity for detecting moderate/severe dysplasia, carcinoma in situ, and micro-invasive cancer. LIFE is intended for use as an adjunct to white-light bronchoscopy and should be used by operators trained in device techniques.

    Definitions

    inv-28: LIFE (Light Imaging Fluorescence Endoscope) — definition and mechanism
    DefinitionLIFE (Light Imaging Fluorescence Endoscope) is an autofluorescence bronchoscopy system that uses blue laser light via a flexible fiberoptic bronchoscope to elicit tissue autofluorescence and project images to guide biopsy
    MechanismDifferentiates normal bronchial mucosa from dysplastic/carcinomatous mucosa in real time by detecting differences in autofluorescence
    Usage restrictionIntended for use only in conjunction with white-light bronchoscopy and limited to physicians trained in flexible fiber optic bronchoscopy and LIFE device use
    Contraindication noteShould not be used in combination with photosensitizing agents
    inv-29: Hyperpolarized Xenon-129 MRI — definition and regulatory note (FDA approval referenced)
    DefinitionHyperpolarized Xenon-129 MRI is an MRI technique using inhaled hyperpolarized Xe-129 gas to evaluate regional lung ventilation and gas exchange
    Regulatory noteFDA approved Xenon-129 gas (Xe-129) for evaluation of lung ventilation in patients aged 12 years or older (Dec 2022)
    Operational considerationsRequires specialized equipment to process inhaled gas; gas must be inhaled within ~5 minutes of hyperpolarization and MRI must begin immediately after a single-breath hold
    Data limitationThis modality does not correlate directly with standard lung function testing; additional measurements are needed for clinical interpretation
    inv-30: 3D-SBCSI (3D single-breath chemical shift imaging) — definition and measurement outputs
    Definition3D-SBCSI (3D single-breath chemical shift imaging) is a hybrid MR spectroscopic imaging modality using hyperpolarized Xe-129 to acquire voxel-level spectra after a single breath-hold
    Measured outputsAnalyzes voxel Xe-129 spectra for peak ratios, chemical shifts, and T2* relaxation times (e.g., tissue/RBC ratios, RBC chemical shift, RBC T2*)
    Physiologic applicationsProvides markers sensitive to disease physiology to help differentiate IPF, CF, COPD, and healthy lungs
    Acquisition detailsUses separate breath-holds for proton, Xe-129 ventilation, and 3D-SBCSI images with RF chest coil tuned to Xe-129
    inv-31: Dynamic-ventilation CT with color-map software — definition and intended visualization purpose
    DefinitionDynamic-ventilation CT is a four-dimensional CT acquisition during free breathing combined with image analysis software that generates color maps to visualize movement differences between lung surface and chest wall
    Intended visualization purposeColor-map software visualizes differential motion to detect parietal pleural invasion/adhesion and improve preoperative assessment
    Reported diagnostic performanceIn a pilot study, software-assisted 4D dynamic-ventilation CT achieved sensitivity 100% and specificity 100% for pleural invasion/adhesion (AUC 1.000) versus conventional CT
    LimitationsEvidence is preliminary with small patient cohorts; further larger studies are needed to verify clinical utility
    inv-32: References / device prescribing information — reference to Polarean Xenoview prescribing information and study refs
    Polarean Xenoview prescribing informationPolarean, Inc. Xenoview (xenon Xe-129 hyperpolarized), for oral inhalation. Prescribing Information. Durham, NC: Polarean; revised December 2022.
    Selected study referencesReferences include Hahn et al. (Radiology 2022) on 129Xe MR spectroscopy in IPF and Mata et al. (Tomography 2021) evaluating regional lung function with 129Xe MRI
    Autofluorescence/LIFE referencesKey LIFE/AFB references include Lam et al. and Palcic et al. (refs 17, 28, 19) addressing detection/localization of early lung cancer using fluorescence techniques
    Dynamic-ventilation CT study refYamashiro et al. (Eur Radiol 2019) and Nagatani et al. (Eur J Radiol 2020) describe software-assisted 4D dynamic-ventilation CT for pleural invasion/adhesion assessment

    References and Revision History

    References for clinical and investigational lung imaging modalities — numbered

    Numbered references: 10. Hahn AD, Carey KJ, Barton GP, et al. Radiology. 2022;305(3):688-696.; 11. Herth FJ, Ernst A, Becker HD. Respiration. 2003;70(4):395-398.; 12. Hirsch FR, Franklin WA, Gazdar AF, et al. Clin Cancer Res. 2001;7(1):5-12.; 13. Khanavkar B, Gnudi F, Muti A, et al. Pneumologie. 1998;52(2):71-76.; 14. Kurie JM, Lee JS, Morice RC, et al. J Natl Cancer Inst. 1998;90(13):991-998.; 15. Lam B, Wong MP, Fung SL, et al. Eur Respir J. 2006;28(5):915-919.; 16. Lam S, Becker HD. Chest Surg Clin N Am. 1996;6(2):363-380.; 17. Lam S, Hung JY, Kennedy SM, et al. Am Rev Respir Dis. 1992;146(6):1458-1461.; 18. Lam S, Kennedy T, Unger M, et al. Chest. 1998;113(3):696-702.; 19. Lam S, MacAulay C, Hung J, et al. J Thorac Cardiovasc Surg. 1993;105(6):1035-1040.; 20. Lam S, MacAulay C, Palcic B. Chest. 1993;103(1 Suppl):12S-14S.; 21. Lee P, Sutedja TG. Curr Opin Pulm Med. 2007;13(4):243-248.; 22. Lee P, van den Berg RM, Lam S, et al. Clin Cancer Res. 2009;15(14):4700-4705.; 23. Loewen G, Natarajan N, Tan D, et al. Thorax. 2007;62(4):335-340.; 24. Mata J, Guan S, Qing K, et al. Tomography. 2021;7(3):452-465.; 25. Matheson AM, McIntosh MJ, Kooner HK, et al. Radiology. 2022;305(2).; 26. Mummy DG, Bier EA, Wang Z, et al. Radiology. 2021;301(1):211-220.; 27. Nagatani Y, Hashimoto M, Oshio Y, et al. Eur J Radiol. 2020;133:109347.; 28. Palcic B, Lam S, Hung J, MacAulay C. Chest. 1991;99(3):742-743.; 29. Polarean, Inc. Xenoview prescribing information. Dec 2022.; 30. Read C, Janes S, George J, Spiro S. Prim Care Respir J. 2006;15(6):332-336.; 31. Shankar LK, Sullivan DC. J Clin Oncol. 2005;23(14):3203-3211.; 32. Short MA, Lam S, McWilliams AM, et al. J Thorac Oncol. 2011;6(7):1206-1214.; 33. Sutedja TG, Codrington H, Risse EK, et al. Chest. 2001;120(4):1327-1332.; 34. van Rens MT, Schramel FM, Elbers JR, et al. Lung Cancer. 2001;32(1):13-18.; 35. Yamashiro T, Moriya H, Tsubakimoto M, et al. Eur Radiol. 2019;29(10):5247-5252.; 36. Zeng H, Petek M, Zorman MT, et al. Opt Lett. 2004;29(6):587-589.

    These are the numbered references cited in the policy.